Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Thalia Therap. (THAT) Share Price

Price 0.65p on 03-07-2026 at 10:25:14
Change 0.00p 0%
Buy 0.70p
Sell 0.60p
Last Trade: Sell 161,567.00 at 0.644p
Day's Volume: 181,011
Last Close: 0.65p
Open: 0.65p
ISIN: GB00BYW8QM32
Day's Range 0.65p - 0.65p
52wk Range: 0.375p - 0.90p
Market Capitalisation: £5.41m
VWAP: 0.650015p
Shares in Issue: 832.28m

Thalia Therap. (THAT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 161,567 0.644p Ordinary
10:46:07 - 03-Jul-26
Buy* 19,230 0.70p Ordinary
10:35:26 - 03-Jul-26
Buy* 214 0.70p Ordinary
08:31:08 - 03-Jul-26
Sell* 75,000 0.6415p Ordinary
14:10:06 - 02-Jul-26
Buy* 25,000 0.69p Ordinary
13:01:51 - 02-Jul-26
Buy* 1,628 0.70p SI Trade
08:20:57 - 02-Jul-26
Sell* 1,527 0.60p SI Trade
16:14:09 - 01-Jul-26
Buy* 1,428 0.70p SI Trade
16:14:09 - 01-Jul-26
Buy* 8,271 0.70p SI Trade
16:14:09 - 01-Jul-26
Buy* 1,000 0.70p SI Trade
16:14:09 - 01-Jul-26
See more Thalia Therap. trades

Thalia Therap. (THAT) Share Price History

Time period:
to
Date Open High Low Close Volume
2nd Jul 2026 (Thu) 0.65 0.65 0.65 0.65 101,628
1st Jul 2026 (Wed) 0.65 0.65 0.65 0.65 9,735,127
30th Jun 2026 (Tue) 0.65 0.65 0.65 0.65 215,510
29th Jun 2026 (Mon) 0.65 0.65 0.65 0.65 12,281
26th Jun 2026 (Fri) 0.65 0.65 0.65 0.65 3,354,642
25th Jun 2026 (Thu) 0.675 0.675 0.65 0.65 5,108,118
24th Jun 2026 (Wed) 0.625 0.675 0.625 0.675 11,671,501
23rd Jun 2026 (Tue) 0.575 0.575 0.575 0.575 2,024
22nd Jun 2026 (Mon) 0.575 0.575 0.575 0.575 256,357
19th Jun 2026 (Fri) 0.575 0.575 0.575 0.575 168,565
18th Jun 2026 (Thu) 0.575 0.575 0.575 0.575 116,484
17th Jun 2026 (Wed) 0.575 0.575 0.575 0.575 171,492
16th Jun 2026 (Tue) 0.575 0.575 0.575 0.575 17,338
15th Jun 2026 (Mon) 0.575 0.575 0.575 0.575 490,949
12th Jun 2026 (Fri) 0.575 0.575 0.575 0.575 7,058
11th Jun 2026 (Thu) 0.575 0.575 0.575 0.575 172,023
10th Jun 2026 (Wed) 0.575 0.575 0.575 0.575 643,805
9th Jun 2026 (Tue) 0.575 0.575 0.575 0.575 70,140
8th Jun 2026 (Mon) 0.60 0.60 0.575 0.575 864,928
5th Jun 2026 (Fri) 0.60 0.60 0.60 0.60 11,146
4th Jun 2026 (Thu) 0.65 0.65 0.575 0.60 1,889,214
3rd Jun 2026 (Wed) 0.65 0.65 0.65 0.65 1,020,829
See more Thalia Therap. price history

Thalia Therap. (THAT) Regulatory News

Date Source Headline
24th Jun 2026 3:21 pm RNS Posting of Annual Report and Notice of AGM
24th Jun 2026 7:00 am RNS Acquisition and £2.75 million Fundraise
23rd Jun 2026 5:04 pm RNS Final Results
9th Jun 2026 7:00 am RNS-R New article: RNA medicine enters its second act
2nd Jun 2026 8:57 am RNS-R CEO Interview
13th May 2026 11:12 am RNS-R CEO Interview: Thalia’s RNA Therapeutics Strategy
20th Apr 2026 7:00 am RNS Change of Registered Address
See more Thalia Therap. regulatory news

Thalia Therap. (THAT) Share News

TRADING UPDATES: Tullow Oil makes partial notes repayment

24th Jun 2026 13:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

LONDON MARKET MIDDAY: Stocks mixed but no "contagion" from US sell-off

24th Jun 2026 11:59

(Alliance News) - The FTSE 100 was higher at midday on Wednesday, boosted by Segro after it rejected an "opportunistically timed" takeover proposal, and as the US and Iran reportedly prepare to restart 'technical talks'. Read More

IN BRIEF: Thalia Therapeutics eyes adding microRNA therapeutic asset

23rd Jun 2026 20:20

Thalia Therapeutics PLC - biotechnology company developing innovative RNA therapeutics - Pretax loss is flat at GBP1.2 million in 2025 when compared to the year prior. Loss per share is 0.17 pence versus 0.31p the year before, revenue is little changed at GBP7,264 versus GBP7,282. Research and development costs fall to GBP214,120 from GBP390,387 and general and administration costs rise to GBP1.0 million from GBP837,996. "Alongside our internally developed assets, we are in advanced stages of potentially adding a clinical-stage microRNA therapeutic asset to the company's portfolio. If successful, this, combined with the continued advancement of Nuvec, our dual-targeting siRNA programme, is the first step in creating a differentiated and valuable RNA therapeutics company," says Chief Executive David Solomon. Read More

EARNINGS AND TRADING: Asia Strategic Holdings revenue declines

9th Jun 2026 18:19

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

WINNERS & LOSERS: Oracle Power shines; Ferrexpo output plunges

15th Apr 2026 10:10

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Wednesday. Read More

See more Thalia Therap. news
FTSE 100 Latest
Value10,607.23
Change-45.64

Login to your account

Forgot Password?

Not Registered